BioCryst’s chief R&D officer to depart for CEO role elsewhere

RESEARCH TRIANGLE PARK, N.C. - BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), a biotechnology company with a market capitalization of $1.74 billion and impressive revenue growth of 46% over the last twelve months, announced Monday that Dr. Helen Thackray, chief research and development officer, will leave the company on September 1, 2025, and transition to an advisory role through year-end.According to InvestingPro analysis, BioCryst shows promising potential with analysts expecting profitability this year.

Thackray, who joined BioCryst’s board of directors in 2019 before becoming chief R&D officer in 2021, was a finalist in the company’s recent CEO succession process. Following the completion of that process, she has decided to pursue a chief executive leadership opportunity elsewhere.

During her tenure, Thackray led several key initiatives including the launch of a new protein therapeutics platform with BCX17725 for Netherton syndrome, the advancement of the avoralstat program for diabetic macular edema, and progress on the ORLADEYO pediatric program.

"I am deeply grateful to Helen for the contributions she has made to BioCryst," said Jon Stonehouse, chief executive officer of BioCryst. "I am excited for her as she seeks her next role as a leader in our industry."

Thackray stated, "I applaud the value BioCryst has delivered to individuals living with HAE in the last five years and am proud to have contributed to this with the potential upcoming addition of oral prophylaxis for children with HAE."

BioCryst Pharmaceuticals is a biotechnology company focused on developing treatments for hereditary angioedema and other rare diseases. The company has commercialized ORLADEYO, an oral, once-daily plasma kallikrein inhibitor.

This information is based on a company press release statement.

In other recent news, BioCryst Pharmaceuticals Inc. reported a notable earnings beat for the second quarter of 2025. The company announced earnings per share of $0.15, significantly surpassing the forecast of $0.01, marking a 1400% surprise. Additionally, BioCryst’s revenue reached $163.4 million, exceeding expectations of $149.82 million. These financial results highlight the company’s strong performance during the quarter. The announcement has drawn attention from investors and analysts alike. While the stock experienced notable movement, the focus remains on the company’s financial achievements. These recent developments underscore BioCryst’s ability to outperform market expectations.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.